Public annual accounts

''DR. ISABELLE VANDE BROEK, HEMATOLOOG'' financials

Name: ''DR. ISABELLE VANDE BROEK, HEMATOLOOG'' financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for ''DR. ISABELLE VANDE BROEK, HEMATOLOOG'', with comparable measures and links to available source documents.

Company overview

Registry number

0834764281

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 28, 2026

Financial evidence

Latest movements for ''DR. ISABELLE VANDE BROEK, HEMATOLOOG''

2025 versus 2024

Operating line: €273,469
EBITDA: €273,469
Total assets: €861,668
Equity: €712,153

EBITDA margin +100% · Equity ratio +82.6%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202530 Jun 2025	€273,469	€273,469	€861,668	€712,153	-
202430 Jun 2024	€223,633	€220,500	€1,146,121	€987,157	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report

Fiscal year

Gross margin

EBITDA

Total assets

Equity

Filing

202530 Jun 2025

€273,469

€861,668

€712,153

202430 Jun 2024

€223,633

€220,500

€1,146,121

€987,157